<DOC>
	<DOCNO>NCT00113581</DOCNO>
	<brief_summary>The main purpose study test safety tolerability effectiveness new treatment , EMD 72000 ( matuzumab ) , advance oesophagogastric cancer combination chemotherapy regimen ECX ( epirubicin , cisplatin capecitabine ) . In addition study look pharmacokinetic ( body take drug ) pharmacodynamic parameter ( drug body ) .</brief_summary>
	<brief_title>Safety Study EMD 72000 Combination With ECX ( Epirubicin , Cisplatin Capecitabine ) Oesophagogastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Advanced , recurrent metastatic gastric adenocarcinoma adenocarcinoma lower third esophagus EGFR positive tumor KPS great 60 Normal cardiac function Adequate liver bone marrow function GFR great 60 ml/minute Previous chemotherapy Uncontrolled angina pectoris , heart failure , clinically significant uncontrolled cardiac arrythmias Clinically significant ECG cardiac history Radiotherapy surgery within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>EMD 72000</keyword>
	<keyword>matuzumab</keyword>
	<keyword>Esophageal adenocarcinoma</keyword>
	<keyword>Gastric adenocarcinoma</keyword>
</DOC>